Nuvectis Pharma, Inc. (NVCT)

5,98 -0,17 (-2,76%) Al cierre: 04:00PM EDT

Nuvectis Pharma, Inc.

1 Bridge Plaza
Suite 275
Fort Lee, NJ 07024
United States
201 614 3150
https://www.nuvectis.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 13

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Ron Bentsur M.B.A.	Co-Founder, Chairman, CEO & President	1,12M	N/A	1966
Dr. Enrique Poradosu Ph.D.	Co-Founder, Executive VP, Chief Scientific & Business Officer	705,5k	N/A	1967
Mr. Shay Shemesh	Co-Founder, Executive VP, Chief Development & Operations Officer	705,5k	N/A	1984
Mr. Michael Carson CPA	Vice President of Finance	N/A	N/A	1976

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Gobierno corporativo

El ISS Governance QualityScore de Nuvectis Pharma, Inc., a día 1 de mayo de 2024, es 9. Las puntuaciones base son Auditoría: 8; Tablero: 10; Derechos de los accionistas: 6; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.